Alopecia Areata
Pipeline by Development Stage
Drug Modality Breakdown
Dermatology is a $292M market that is mature and consolidating, dominated by a single blockbuster approaching loss of exclusivity.
Key Trends
- HUMIRA (adalimumab) dominates 88% of market spending but faces LOE in near-term, creating vulnerability
- Novel mechanisms like aryl hydrocarbon receptor agonists gaining traction with emerging products in peak lifecycle
- Substantial clinical trial activity (812 trials) suggests ongoing innovation pipeline despite mature market
Career Verdict
Dermatology offers stable near-term opportunities but requires strategic positioning given patent cliff risk and limited market size compared to other therapeutic areas.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | HUMIRA (adalimumab) | AbbVie | $258M | 88% | LOE_APPROACHING | Declining | |
| 2 | VTAMA (tapinarof) | Merck & Co. | $19M | 6% | PEAK | Growing | 13.0yr |
| 3 | ORACEA (doxycycline) | Galderma | $4M | 1% | LOE_APPROACHING | Declining | 1.1yr |
Drug Class Breakdown
Patent cliff looming
Emerging innovation
Mature segment
Niche applications
Career Outlook
StableDermatology represents a stable but narrow career path with limited growth compared to larger therapeutic areas; compensation is competitive in Commercial and Medical Affairs but R&D opportunities are scarce. HUMIRA's patent cliff creates near-term uncertainty for AbbVie but may drive restructuring and new product launches elsewhere. Market consolidation around a few large players (AbbVie, Regeneron, Merck) limits startup/biotech opportunities.
Breaking In
Enter via Commercial or Medical Affairs roles where hiring is highest; dermatology has lower scientific barrier to entry than oncology but requires strong relationship-building and market access acumen.
For Experienced Professionals
Leverage HUMIRA transition expertise or develop specialty in emerging mechanisms (retinoids, AhR agonists); consider moving to larger franchises (immunology, oncology) if seeking higher growth trajectory.
In-Demand Skills
Best For
Hiring Landscape
Dermatology shows concentrated hiring at AbbVie (52 positions) and Regeneron (46 positions), with Commercial roles dominating (89 jobs, $188K avg salary) and Medical Affairs roles commanding premium compensation ($386K avg). Limited R&D hiring (8 positions) suggests mature drug development phase with emphasis on commercialization and market access.
By Department
Commercial and Medical Affairs roles offer strong compensation and growth, but overall job market is small; best for professionals seeking revenue-generating functions rather than discovery roles.
On Market (2)
Approved therapies currently available
Competitive Landscape
23 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Showing 15 of 48 trials with date data
Clinical Trials (49)
Total enrollment: 62,098 patients across 49 trials
A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.
Long-Term PF-06651600 for the Treatment of Alopecia Areata
A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata
PF-06651600 for the Treatment of Alopecia Areata
A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata
A Study of LAD603 in Adults With Alopecia Areata
Evaluating the Effectiveness and Tolerance of Baricitinib in the Treatment of Acute Alopecia Areata With Active Hair Shedding: A Prospective Open-Label Study
Baricitinib for Central Centrifugal Cicatricial Alopecia in Adults of African Descent
Ritlecitinib in Patients With Keloids or Those Undergoing Keloidectomy
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA)
A Study of Efficacy and Safety of Rosnilimab in Subjects With Moderate to Severe Ulcerative Colitis (ROSETTA)
A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA)
A Study of Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Rheumatoid Arthritis (RENOIR)
Regeneron AA Multicenter (Dupilumab)
Study of EQ101 in Adult Subjects With Moderate to Severe Alopecia Areata
Clinical Application of Stem Cell Educator Therapy in Alopecia Areata
Study of DAXDILIMAB for the Treatment of Moderate-to-Severe Alopecia Areata
A Phase 2 Placebo Controlled, Clinical Trial Designed to Assess the Efficacy, Safety and Dose Response Characterisation of STS01 for the Treatment of Mild-moderate Alopecia Areata (AA)
A Study to Evaluate the Efficacy and Safety of Rosnilimab (ANB030) in Treatment of Subjects With Moderate-to-Severe Alopecia Areata
Phase 2 Trial of BNZ-1 in Patients With Moderate to Severe Alopecia Areata
Treatment of Alopecia Areata (AA) With Dupilumab in Patients With and Without Atopic Dermatitis (AD)
Efficacy of Twice Daily Application of LEO 124249 Ointment 30 mg/g for 12 Weeks on Eyebrow Alopecia Areata.
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
LEO 124249 Ointment in the Treatment of Alopecia Areata
A Study of Secukinumab for the Treatment of Alopecia Areata
A Phase 1/2 Study to Evaluate the Safety and Efficacy of Dibotatug (DR-01) in Adults With Bone Marrow Failure Syndromes
Stem Cell Educator Therapy in Alopecia Areata
A Study Testing the Safety and Effects of FB102 in Healthy Volunteers
A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Severe to Very Severe Alopecia Areata.
A Study of DR-01 in Subjects With Alopecia Areata and Vitiligo
A Study to Learn About How Different Forms of the Study Medicine Called Ritlecitinib Pass the Intestines of Healthy Male Adults When Taken With or Without Food
A Study to Learn About Three Forms of The Study Medicine (Ritlecitinib) in Healthy Adults
A Single and Multiple Ascending Dose Study of LAD603 in Healthy Subjects
A Study to Assess Two Forms of The Study Medicine (Ritlecitinib) in Healthy Adult Participants
A Study to Learn About the Study Medicine (Called Ritlecitinib) For the Potential Treatment of Severe Alopecia Areata (AA) In Children 6 To Less Than 12 Years of Age
Comparative Efficacy of Tacrolimus and Clobetasol Propionate in Alopecia Areata
A Target Occupancy Study With Ritlecitinib.
A Single Dose Study To Test Two Pediatric Forms Of Ritlecitinib Compared With Adult Ritlecitinib In Healthy Adults
Availability of Dibotatug (DR-01) Outside Clinical Trials Via Expanded Access for Eligible Participants
Real-World Effectiveness of Ritlecitinib in Alopecia Areata Patients in the US: A Retrospective Analysis Using EHR and Claims Data
Utilization and Effectiveness of Ritlecitinib in a Real-World Population With Severe AA in the US
A Study to Learn About Litfulo Capsule in People With Severe Alopecia Areata in Routine Clinical Practice.
A Study to Learn About the Medicine Called Ritlecitinib in Adults With Severe Alopecia Areata in Real-world Settings
Characterization And Clinical Outcomes of AA Patients Treated With Ritlecitinib
Litfulo Capsules Special Investigation
Quantification of the Socio-economic Multifacet Burden of Alopecia Areata and Identification of the Associated Factors
The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
Biocellular-Cellular Regenerative Treatment Scaring Alopecia and Alopecia Areata
Related Jobs in Dermatology
Dermatology Access & Reimbursement Manager (ARM) -Boston, MA
Director, Consumer Marketing – US Dermatology
Board Certified Medical Director - Dermatology - Remote Based
Field Reimbursement Manager - (Wilmington, DE) Dermatology
Specialty Business Manager - Dermatology - Topeka, KS
Specialty/ Senior Specialty Representative - Dermatology - Oklahoma City, OK
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.